L1 (CAM) (CD171) in ovarian serous neoplasms

Purpose of the investigation: The evaluation of L1 (CAM) as a tumor progression marker and as a prognostic factor in serous ovarian tumors. Methods: L1 (CAM) protein expression was assessed by immunohistochemistry and Western blot in serous ovarian tumors [cystadenomas (n = 20), borderline tumors (n = 14) and carcinomas (n = 47)], and was correlated with stage,grade, progression-free survival time (PFS) and overall survival. Results: L1 (CAM) immunoreactivity correlated significantly with stage and grade. It increased from benign tumors to early carcinomas and to advanced stage carcinomas progressively and significantly. In Stage III G3 carcinoma patients, low L1 (CAM) expressing tumors exhibited better response to chemotherapy and were associated with statistically significantly longer PFS (p = 0.002). Conclusion: L1 (CAM) expression represents a novel diagnostic marker in serous ovarian neoplasms that shows characteristics of tumor progression. L1 expression was associated with chemotherapy response.

L1 (CAM); CD171; Ovarian cancer; Biomarker; Prognostic factor; Tumor progression

[1] Moos M., Tacke R., Scherer H.., Teplow D, Fruh K., Schachner M.: “Neural adhesion molecule L1 as a member of the immunoglobulin superfamily with binding domains similar to fibronectin”. Nature, 1988, 334, 701.

[2] Grumet M., Edelman G.M.: “Neuron-glia cell adhesion molecule interacts with neurons and astroglia via different binding mechanisms”. J. Cell Biol., 1988, 106, 487.

[3] Miura M., Asou H., Kobayashi M., Uyemura K.: Functional expression of a full-length eDNA coding for rat neural cell adhesion mnolecule LI mediates homophilic intercellular adhesion and migration of cerebellar neurons”. J. Biol. Chem., 1992, 267, 10752.

[4] Lemmon V., Fan K. L., Lagermaur C.: “LI-mediated axon outgrowth occurs via a homophilie bindimig mechanism”. Neuron, 1989, 2, 1597.

[5] Zhao X., Siu C.H.: “Colocalization of the homophilic binding site and the neuritogenic activity of the cell adhesion molecule L1 to its second Ig-like domain”. J. Biol. Chem.,1995, 270, 29413.

[6] Kadmon G., Kowitz A., Altevogt P., Schachner M.: “The neural cell adhesion molecule N-CAM enhances L1-dependent cell-cell interactions”. J. Cell. Biol., 1990, 110, 193.

[7] Kuhn T.B., Stoeckli F.T., Condrau M.A., Rathjen F.G., Sonderegger P.: “Neurite outgrowth on immobilized axonin-I is mediated by a heterophilie interaction with LI (G4)”. J. Cell. Biol., 1991, 115, 1113.

[8] Felsenfeld D.P., Hynes M.A., Skoler K.M., Furley A.J., Jessell T.M.: “TAG-1 can mediate homophilic binding, but neurite outgrowth on TAG-1 requires an L1-like molecule and beta 1 integrins”. Neuron., 1994, 12, 675.

[9] Ruppert M., Aigner S., Hubbe M., Yagita H., Altevogt P.: “The LI adhesion molecule is a cellular ligand for VLA-5”. J. Cell. Biol., 1995, 131, 1881.

[10] Montgomery A.M.P., Becker J.C., Siu C-H., Lemmon V.P., Cheresh D.A., Paneook J.D. et al.: “Human neural cell adhesion molecule LI and rat homologue NILE are ligands for integrin a,b3”. J. Cell. Biol., 1996, 132, 475.

[11] Grumet M., Friedlander D.R., Edelman G.M.: “Evidence for the binding of Ng-CAM to laminin”. Cell Adhes. Commun., 1993, 1, 177.

[12] Hall H., Carbonetto S., Schachner M.: “Ll/HNK-l carbohydrateamid and b1- integrin-dependent neural cell adhesion to laminin-I”. J. Neurochem., 1997, 68, 544.

[13] Friedlander D.R., Milev P., Karthikeyan L., Margolis R.K., Margolis R.U., Grumet M.: “The neuronal chondroitin sulfate proteoglycan neurocan binds to the neural cell adhesion molecules Ng- CAM/L1/NILE and N-CAM, and inhibits neuronal adhesion and, neurite outgrowth”. J. Cell. Biol., 1994, 125, 669.

[14] Bateman A., Jouet M., MacFarlane J., Du J.S., Kenwrick S., Chothia C.: “Outline structure of the human L1 cell adhesion molecule and the sites where mutations cause neurological disorders”. EMBO J., 1996, 15, 6050.

[15] Vits L., Van Camp G., Coucke P., Fransen E., De Boulle K., Reyniers E. et al.: “MASA syndrome is due to mutations in the neural cell adhesion gene L1CAM”. Nat. Genet., 1994, 7, 408.

[16] Wong E.V., Kenwrick S., Willems P., Lemmon V.: “Mutations in the cell adhesion molecule L1 cause mental retardation”. Trends Neurosci., 1995, 18, 168.

[17] Ebeling O., Duczmal A., Aigner S., Geiger C., Schöllhammer S., Kemshead J.T. et al.: “L1 adhesion molecule on human lymphocytes and monocytes: expression and involvement in binding to alpha v beta 3 integrin”. Eur. J. Immunol., 1996, 26, 2508.

[18] Pancook J.D., Reisfeld R.A., Varki N., Vitiello A., Fox R.I., Montgomery A.M.: “Expression and regulation of the neural cell adhesion molecule L1 on human cells of myelomonocytic and lymphoid origin”. J. Immunol., 1997, 158, 4413.

[19] Katayama M., Iwamatsu A., Masutani H., Furuke K., Takeda K., Wada H. et al.: “Expression of neural cell adhesion molecule L1 in human lung cancer cell lines”. Cell. Struct. Funct., 1997, 22, 511.

[20] Fogel M., Gutwein P., Mechtersheimer S., Riedle S., Stoeck A., Smirnov A. et al.: “L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas”. Lancet, 2003, 362, 869.

[21] Fogel M., Huszar M., Altevogt P., Ben-Arie A.: “L1 (CD171) as a novel biomarker for ovarian and endometrial carcinomas”. Expert. Rev. Mol. Diagn., 2004, 4, 455.

[22] Huszar M., Moldenhauer G., Gschwend V., Ben-Arie A., Altevogt P., Fogel M.: “Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy”. Hum. Pathol., 2006, 37, 1000.

[23] Stoeck A., Gast D., Sanderson M.P., Issa Y., Gutwein P., Altevogt P.: “L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells”. Gynecol. Oncol., 2007, 104, 461.

[24] Gavert N., Conacci-Sorrell M., Gast D., Schneider A., Altevogt P., Brabletz T. et al.: “L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers”. J. Cell. Biol., 2005, 168, 633.

[25] Primiano T., Baig M., Maliyekkel A., Chang B.D., Fellars S., Sadhu J. et al.: “Identification of potential anticancer drug targets through the selection of growth-inhibitory genetic suppressor elements”. Cancer Cell., 2003, 4, 41.

[26] Arlt M.J., Novak-Hofer I., Gast D., Gschwend V., Moldenhauer G., Grunberg J. et al.: “Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti- L1-cell adhesion molecule monoclonal antibody treatment”. Cancer Res., 2006, 66, 936.